

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS, INC.
Petitioner,

v.

SENJU PHARMACEUTICAL CO., LTD.
Patent Owner.

U.S. Patent No. 8,784,789 to Higashiyama
Issue Date: July 22, 2014

Title: Aqueous Liquid Preparations and Light-Stabilized Aqueous Liquid
Preparations

Inter Partes Review No.: IPR2016-00626

Petition's Exhibit List for *Inter Partes* Review of U.S. Patent No. 8,784,789

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Petitioner's Exhibit List

<i>Petitioner Exhibit #</i>	<i>Description</i>
1001	Higashiyama, U.S. Patent No. 8,784,789, "Aqueous Liquid Preparations and Light-Stabilized Aqueous Liquid Preparations" ("the '789 patent")
1002	Higashiyama, U.S. Patent No. 8,877,168 "Aqueous Liquid Preparations and Light-Stabilized Aqueous Liquid Preparations" ("the '168 patent")
1003	Declaration of Dr. Amiji
1004	U.S. Patent No. 6,174,914 ("Yanni")
1005	Remington: The Science and Practice of Pharmacy 20th Ed. ("Hecht")
1006	Lloyd V. Allen Jr. et al. "Compounding Ophthalmic Preparations," International Journal of Pharmaceutical Compounding 2(3) (1998) ("Allen")
1007	Chemical and Pharmaceutical Bulletin 50(2) ("Araki I")
1008	Press Release "Tanabe Seiyaku Granted Rights for Bepotastine Besilate for Ophthalmic [sic] Use to Senju Seiyaku (Japan)" ("Tanabe")
1009	PCT International Patent Publication No. WO 01/080858 ("Araki II")
1010	Antihistamines: topical vs oral administration, Clinical and Experimental Allergy 26(3):11-17 (1996) ("Davies")
1011	"Stability Testing: Photostability Testing of New Drug Substances and Products" ("ICH Guideline")
1012	"Formulation of a Stable Parenteral Product; Clonidine Hydrochloride Injection," PDA Journal of Pharmaceutical Science & Technology 56(6):320-325 (1998) ("Kostecka")
1013	Photoreactivity of LY277359 Maleate, a 5- Hydroxytryptamine ₃ (5-HT ₃) Receptor Antagonist, in Solution, Pharmaceutical Research 8(10):1215-1222 (1991) ("Mosher")
1014	Reserved
1015	Press Release "Regarding Extended Indication for Selective Histamine H ₁ Receptor Antagonist/Anti-Allergic Agent Talion® Tablets 5 and Talion® Tablets 10 in Treating Pruritus/Itching Accompanying Urticaria and Other Skin Diseases" ("Talion Press Release")

1016	Remington's Pharmaceutical Sciences, pp. 1410-1419 (1980) ("Remington").
1017	European Patent Publication No. EP 0 949 260 ("Kita")
1018	CV of Dr. Amiji
1019	Declaration of Higashiyama of Nov. 6, 2007
1020	Supplemental Amendment of Nov. 13, 2007
1021	Final Office Action of Feb. 8, 2008
1022	Declaration of Higashiyama of Dec. 22, 2008
1023	Amendment of Jan. 5, 2009
1024	Office Action of May 8, 2009
1025	Office Action of April 9, 2010
1026	Final Office Action of Dec. 20, 2010
1027	Declaration of Higashiyama of Sept., 11, 2012
1028	Supplemental Amendment of Sept. 14, 2012
1029	Office Action of Aug. 30, 2013
1030	Amendment of May 30, 2014
1031	Notice of Allowance of June 12, 2014
1032	Amendment of April 24, 2012
1033	Final Office Action of Apr. 30, 2014